Data Insights

Neratinib by Puma Biotechnology for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Neratinib is under clinical development by Puma Biotechnology and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Triple-Negative Breast Cancer (TNBC)

Data Insights

Neratinib by Puma Biotechnology for Solid Tumor: Likelihood of Approval

Neratinib is under clinical development by Puma Biotechnology and currently in Phase II for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Solid Tumor

Data Insights

Neratinib by Puma Biotechnology for Non-Small Cell Lung Cancer: Likelihood of Approval

Neratinib is under clinical development by Puma Biotechnology and currently in Phase II for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Non-Small Cell Lung Cancer

Data Insights

Neratinib by Puma Biotechnology for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Neratinib is under clinical development by Puma Biotechnology and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Neratinib by Puma Biotechnology for Prostate Cancer: Likelihood of Approval

Neratinib is under clinical development by Puma Biotechnology and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Prostate Cancer

Data Insights

Neratinib by Puma Biotechnology for Pancreatic Cancer: Likelihood of Approval

Neratinib is under clinical development by Puma Biotechnology and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Pancreatic Cancer

Data Insights

Neratinib by Puma Biotechnology for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Neratinib is under clinical development by Puma Biotechnology and currently in Phase II for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Neratinib by Puma Biotechnology for Esophageal Cancer: Likelihood of Approval

Neratinib is under clinical development by Puma Biotechnology and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Esophageal Cancer

Data Insights

Neratinib by Puma Biotechnology for Melanoma: Likelihood of Approval

Neratinib is under clinical development by Puma Biotechnology and currently in Phase II for Melanoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Melanoma

Data Insights

Neratinib by Puma Biotechnology for Ovarian Cancer: Likelihood of Approval

Neratinib is under clinical development by Puma Biotechnology and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Ovarian Cancer

Data Insights

Neratinib by Puma Biotechnology for Gastric Cancer: Likelihood of Approval

Neratinib is under clinical development by Puma Biotechnology and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Gastric Cancer